Indications for use of ketoconazolein management of metastatic prostate cancer

Franklin C. Lowe, Mitchell H. Bamberger

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Newer methods of androgen ablation for the treatment of metastatic prostatic carcinomahave been developed as alternatives to the standard forms of therapy, oral estrogens and surgical castration. The purpose of this review is to elucidate the indications and to determine the role of ketoconazole in the management of metastatic prostatic cancer. Eighteen patients have been treated with ketoconazole. The indications for usage have included: prompt therapeutic response, when orchiectomy is contraindicated, when estrogens are contraindicated, initial empirical therapy, and hormonally refractory disease. It can also be used in conjunction with luteinizing hormone-releasing hormone analogues. Ketoconazole is excellent for short-term usage prior to bilateral orchiectomy and when prompt therapeutic response is needed but orchiectomy cannot be performed. However, it is not particularly useful for long-term hormonal therapy.

Original languageEnglish (US)
Pages (from-to)541-545
Number of pages5
JournalUrology
Volume36
Issue number6
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Ketoconazole
Orchiectomy
Estrogens
Therapeutics
Castration
Gonadotropin-Releasing Hormone
Androgens

ASJC Scopus subject areas

  • Urology

Cite this

Indications for use of ketoconazolein management of metastatic prostate cancer. / Lowe, Franklin C.; Bamberger, Mitchell H.

In: Urology, Vol. 36, No. 6, 1990, p. 541-545.

Research output: Contribution to journalArticle

Lowe, Franklin C. ; Bamberger, Mitchell H. / Indications for use of ketoconazolein management of metastatic prostate cancer. In: Urology. 1990 ; Vol. 36, No. 6. pp. 541-545.
@article{2501abba96014107a1fca7329b0d400f,
title = "Indications for use of ketoconazolein management of metastatic prostate cancer",
abstract = "Newer methods of androgen ablation for the treatment of metastatic prostatic carcinomahave been developed as alternatives to the standard forms of therapy, oral estrogens and surgical castration. The purpose of this review is to elucidate the indications and to determine the role of ketoconazole in the management of metastatic prostatic cancer. Eighteen patients have been treated with ketoconazole. The indications for usage have included: prompt therapeutic response, when orchiectomy is contraindicated, when estrogens are contraindicated, initial empirical therapy, and hormonally refractory disease. It can also be used in conjunction with luteinizing hormone-releasing hormone analogues. Ketoconazole is excellent for short-term usage prior to bilateral orchiectomy and when prompt therapeutic response is needed but orchiectomy cannot be performed. However, it is not particularly useful for long-term hormonal therapy.",
author = "Lowe, {Franklin C.} and Bamberger, {Mitchell H.}",
year = "1990",
doi = "10.1016/0090-4295(90)80199-W",
language = "English (US)",
volume = "36",
pages = "541--545",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Indications for use of ketoconazolein management of metastatic prostate cancer

AU - Lowe, Franklin C.

AU - Bamberger, Mitchell H.

PY - 1990

Y1 - 1990

N2 - Newer methods of androgen ablation for the treatment of metastatic prostatic carcinomahave been developed as alternatives to the standard forms of therapy, oral estrogens and surgical castration. The purpose of this review is to elucidate the indications and to determine the role of ketoconazole in the management of metastatic prostatic cancer. Eighteen patients have been treated with ketoconazole. The indications for usage have included: prompt therapeutic response, when orchiectomy is contraindicated, when estrogens are contraindicated, initial empirical therapy, and hormonally refractory disease. It can also be used in conjunction with luteinizing hormone-releasing hormone analogues. Ketoconazole is excellent for short-term usage prior to bilateral orchiectomy and when prompt therapeutic response is needed but orchiectomy cannot be performed. However, it is not particularly useful for long-term hormonal therapy.

AB - Newer methods of androgen ablation for the treatment of metastatic prostatic carcinomahave been developed as alternatives to the standard forms of therapy, oral estrogens and surgical castration. The purpose of this review is to elucidate the indications and to determine the role of ketoconazole in the management of metastatic prostatic cancer. Eighteen patients have been treated with ketoconazole. The indications for usage have included: prompt therapeutic response, when orchiectomy is contraindicated, when estrogens are contraindicated, initial empirical therapy, and hormonally refractory disease. It can also be used in conjunction with luteinizing hormone-releasing hormone analogues. Ketoconazole is excellent for short-term usage prior to bilateral orchiectomy and when prompt therapeutic response is needed but orchiectomy cannot be performed. However, it is not particularly useful for long-term hormonal therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025666594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025666594&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(90)80199-W

DO - 10.1016/0090-4295(90)80199-W

M3 - Article

C2 - 2247927

AN - SCOPUS:0025666594

VL - 36

SP - 541

EP - 545

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -